Pomalidomide with dexamethasone is currently approved for use in the UK to treat adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy. If approved, the combination of pomalidomide with bortezomib and dexamethasone will offer a treatment option for patients who have been previously exposed to lenalidomide (including refractory to lenalidomide) ‐ a type of patients for which the outcomes with other novel regimens are uncertain.
Pomalidomide (Imnovid) with bortezomib and dexamethasone for relapsed or refractory multiple myeloma‐ second line and beyond
Interventions: Bortezomib (Velcade; bortezomib mannitol boronic ester) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Pomalidomide (Imnovid; CC-4047; Pomalyst)
Indications: Multiple myeloma (MM)
Therapeutic Areas: Haematological Cancer and Lymphomas